TAT 2009, the 7th International Symposium on Targeted Anticancer Therapies, was held in Amsterdam, March 23-25, 2009. TAT 2009 was the second meeting organized in partnerships with both ESMO and NCI, and attracted well over 400 delegates from over 40 different countries for a high-quality program with broad international participation. About two-thirds of delegates were from Europe and one-third from other parts of the world, underlining the increasingly global character of this series on new drug development in oncology.

TAT 2009 featured over 40 plenary lectures, including the NDDO Honorary Award Lecture 2009, presented by Dr. Napoleone Ferrara (Genentech Inc, South San Francisco, USA) whose pioneering work on Vascular Endothelial Growth Factor (VEGF) has laid the basis for the successful development of VEGF-targeting anti-angiogenic agents which have now entered daily clinical practice. Two Keynotes addressed the role of chemokines and inflammation in cancer (Dr. Frances Balkwill, Barts & The London School of Medicine & Dentistry, London, UK) and insulin-like growth factors as a promising drug target in cancer (Dr. Michael Pollak, McGill University, Montreal, Canada).

If you wish to view the published abstracts of TAT 2009, just click the banner on the right-hand side of this webpage. You will be taken to the website of Annals of Oncology, the official journal of ESMO. Abstracts of all TAT meeings held since 2005 have been published in Annals of Oncology.